Research programme: antibody-drug conjugate therapeutics - CytomX/ImmunoGen

Drug Profile

Research programme: antibody-drug conjugate therapeutics - CytomX/ImmunoGen

Alternative Names: CX-2009; Probody™-drug conjugates - CytomX/ImmunoGen

Latest Information Update: 15 May 2017

Price : $50

At a glance

  • Originator CytomX Therapeutics; ImmunoGen
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 May 2017 CytomX Therapeutics files an IND application for Cancer before May 2017
  • 05 May 2017 CytomX Therapeutics plans to initiate the phase I/II PROCLAIM-CX-2009 trial for Solid tumours (Monotherapy, Metastatic disease, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (NCT03149549)
  • 06 May 2016 CytomX Therapeutics announces intention to submit IND in the first half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top